{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:00:57Z","timestamp":1780722057318,"version":"3.54.1"},"reference-count":36,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: In the immunotherapy era, cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) is increasingly performed after neoadjuvant immune checkpoint inhibitor (ICI)-based therapy. Examination of the nephrectomy specimen may capture the depth of treatment-induced tumor clearance more accurately than size-based radiological criteria alone. However, pathological reporting is highly heterogeneous across studies: residual viable tumor (RVT), necrosis, pT stage, and binary downstaging have all been used, limiting reproducible cross-study comparison. We aimed to characterize this heterogeneity, assess its implications for evidence synthesis, and propose a pragmatic framework for qualitative interpretation. Methods: PRISMA-compliant systematic review of studies reporting pathological response and oncological outcomes in mRCC patients undergoing CN after neoadjuvant systemic therapy (PROSPERO CRD420251154068). A qualitative synthesis was performed. A three-category Pathological Response Category (PRC) framework is proposed to harmonize heterogeneous metrics. Results: Seven retrospective studies (n = 408) were included. Pathological reporting metrics were inconsistent across all studies, preventing formal meta-analysis. Nevertheless, across cohorts reporting survival outcomes, deeper pathological response was directionally associated with more favorable oncologic outcomes. A discordance between radiological and pathological response was observed, including near-complete tumor clearance in patients classified as radiologically stable, reflecting the non-size-based mechanisms of ICI-induced tumor killing. Conclusions: The central finding of this review is not that pathological response predicts survival\u2014which is expected\u2014but that current pathological reporting in the mRCC surgical setting is too heterogeneous to quantify the frequency, depth, or prognostic significance of that response in a reproducible way. Prospective adoption of standardized pathological reporting protocols is the most critical next step for this field.<\/jats:p>","DOI":"10.3390\/cancers18111829","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:38:42Z","timestamp":1780411122000},"page":"1829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prognostic Value of Clinical and Pathological Response to Neoadjuvant Therapy in Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Systematic Review and Clinical Implications"],"prefix":"10.3390","volume":"18","author":[{"given":"Daria","family":"Chernysheva","sequence":"first","affiliation":[{"name":"Institut de Recerca, Hospital Sant Pau, 08041 Barcelona, Spain"},{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4060-3574","authenticated-orcid":false,"given":"Pedro","family":"Hernandez-Pe\u00f1alver","sequence":"additional","affiliation":[{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[{"name":"Institut de Recerca, Hospital Sant Pau, 08041 Barcelona, Spain"},{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6668-4423","authenticated-orcid":false,"given":"Oscar","family":"Rodriguez-Faba","sequence":"additional","affiliation":[{"name":"Uro-Oncology Department, Fundaci\u00f3 Puigvert, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"Ravaud","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaoncol.2018.5543","article-title":"Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial","volume":"5","author":"Bex","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2225386","DOI":"10.1080\/21645515.2023.2225386","article-title":"First-line ICIs in renal cell carcinoma","volume":"19","author":"Fiorentino","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/iju.70207","article-title":"Role of cytoreductive nephrectomy in the immune checkpoint inhibitor era: A multicenter collaborative study","volume":"32","author":"Nukaya","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/iju.15594","article-title":"The role of cytoreductive nephrectomy in the era of immune checkpoint inhibitors: A review of current evidence and ongoing trials","volume":"32","author":"Hara","year":"2025","journal-title":"Int. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Raimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., De Braud, F., Procopio, G., and Prisciandaro, M. (2019). The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in clinical practice. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174263"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.urolonc.2017.05.006","article-title":"Heterogeneity in renal cell carcinoma","volume":"35","author":"Beksac","year":"2017","journal-title":"Urol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-21-0706","article-title":"Deciphering intratumoral molecular heterogeneity in clear cell renal cell carcinoma with a radiogenomics platform","volume":"27","author":"Udayakumar","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_16","unstructured":"U.S. Food and Drug Administration (2020). Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","article-title":"Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neoadjuvant chemotherapy: A case-control matching study","volume":"54","author":"Hermans","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.purol.2018.07.003","article-title":"ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the bladder group of the French Committee of Oncology","volume":"28","author":"Pignot","year":"2018","journal-title":"Prog. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.urolonc.2019.08.012","article-title":"Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma","volume":"37","author":"Singla","year":"2019","journal-title":"Urol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"837.e9","DOI":"10.1016\/j.urolonc.2021.08.022","article-title":"Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival","volume":"39","author":"Pieretti","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_23","first-page":"101","article-title":"Pathologic response to immunotherapy is associated with survival in patients undergoing delayed nephrectomy for metastatic renal cell carcinoma","volume":"9","author":"Khandwala","year":"2025","journal-title":"medRxiv"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/oncolo\/oyad166","article-title":"Pathological outcomes of patients with advanced renal cell carcinoma who receive nephrectomy following immunotherapy","volume":"29","author":"Panian","year":"2024","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.clgc.2023.07.007","article-title":"Outcomes of consolidative nephrectomy following primary immunotherapy in advanced renal cell carcinoma: A multicenter analysis","volume":"21","author":"Hakimi","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"oyaf004","DOI":"10.1093\/oncolo\/oyaf004","article-title":"Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors","volume":"30","author":"Beckermann","year":"2025","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.32074\/1591-951X-N998","article-title":"Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: Tumour response and immune-related renal vasculitis following cytoreductive nephrectomy","volume":"117","author":"Jain","year":"2025","journal-title":"Pathologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1016\/S1470-2045(25)00345-6","article-title":"Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: A systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium","volume":"26","author":"Blackmur","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1148\/rg.2019180178","article-title":"Current challenges in diagnosis and assessment of the response of locally advanced and metastatic renal cell carcinoma","volume":"39","author":"Pirasteh","year":"2019","journal-title":"Radiographics"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.ijrobp.2019.03.012","article-title":"Is multifocal regression a risk factor for ipsilateral breast tumor recurrence in the modern era after neoadjuvant chemotherapy and breast conservation therapy?","volume":"104","author":"Ling","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/his.14644","article-title":"Shrinkage versus fragmentation response in neoadjuvantly treated oesophageal adenocarcinoma: Significant prognostic relevance","volume":"80","author":"Schneider","year":"2022","journal-title":"Histopathology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41590-023-01678-9","article-title":"Decoding the tumor microenvironment with spatial technologies","volume":"24","author":"Walsh","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Iisager, L., Ahrenfeldt, J., Donskov, F., G\u00e5rdmark, T., Soerensen, A.V., Bex, A., Hjorthaug, K., Lodding, P., Sandin, R., and Haug, E.S. (2024). Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: The NORDIC-SUN trial. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11987-3"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:13:33Z","timestamp":1780719213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111829"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111829","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}